These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 27876467)
1. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease. Sameem B; Saeedi M; Mahdavi M; Shafiee A Eur J Med Chem; 2017 Mar; 128():332-345. PubMed ID: 27876467 [TBL] [Abstract][Full Text] [Related]
2. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning. Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530 [TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Nordberg A; Svensson AL Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090 [TBL] [Abstract][Full Text] [Related]
4. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease. Yamali C; Donmez S Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869 [TBL] [Abstract][Full Text] [Related]
5. [Tacrine and its derivatives in the therapy of Alzheimers disease]. Korábečný J; Spilovská K; Benek O; Musílek K; Soukup O; Kuča K Ceska Slov Farm; 2012 Oct; 61(5):210-21. PubMed ID: 23256654 [TBL] [Abstract][Full Text] [Related]
6. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Minarini A; Milelli A; Tumiatti V; Rosini M; Simoni E; Bolognesi ML; Andrisano V; Bartolini M; Motori E; Angeloni C; Hrelia S Neuropharmacology; 2012 Feb; 62(2):997-1003. PubMed ID: 22032870 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core. Lin H; Li Q; Gu K; Zhu J; Jiang X; Chen Y; Sun H Curr Top Med Chem; 2017; 17(27):3000-3016. PubMed ID: 28714419 [TBL] [Abstract][Full Text] [Related]
8. Molecular perception of interactions between bis(7)tacrine and cystamine-tacrine dimer with cholinesterases as the promising proposed agents for the treatment of Alzheimer's disease. Eslami M; Hashemianzadeh SM; Bagherzadeh K; Seyed Sajadi SA J Biomol Struct Dyn; 2016; 34(4):855-69. PubMed ID: 26043757 [TBL] [Abstract][Full Text] [Related]
9. Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease. Wu WY; Dai YC; Li NG; Dong ZX; Gu T; Shi ZH; Xue X; Tang YP; Duan JA J Enzyme Inhib Med Chem; 2017 Dec; 32(1):572-587. PubMed ID: 28133981 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. Przybyłowska M; Dzierzbicka K; Kowalski S; Chmielewska K; Inkielewicz-Stepniak I Curr Neuropharmacol; 2021; 19(8):1323-1344. PubMed ID: 33342413 [TBL] [Abstract][Full Text] [Related]
11. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Musiał A; Bajda M; Malawska B Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717 [TBL] [Abstract][Full Text] [Related]
12. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. Li Q; He S; Chen Y; Feng F; Qu W; Sun H Eur J Med Chem; 2018 Oct; 158():463-477. PubMed ID: 30243151 [TBL] [Abstract][Full Text] [Related]
13. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase. Nachon F; Carletti E; Ronco C; Trovaslet M; Nicolet Y; Jean L; Renard PY Biochem J; 2013 Aug; 453(3):393-9. PubMed ID: 23679855 [TBL] [Abstract][Full Text] [Related]
14. Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines. Romero A; Marco-Contelles J Curr Top Med Chem; 2017; 17(31):3328-3335. PubMed ID: 29332586 [TBL] [Abstract][Full Text] [Related]
15. Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure. de Aquino RA; Modolo LV; Alves RB; de Fatima A Curr Drug Targets; 2013 Mar; 14(3):378-97. PubMed ID: 23176115 [TBL] [Abstract][Full Text] [Related]
16. Tacrine derivatives and Alzheimer's disease. Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341 [TBL] [Abstract][Full Text] [Related]
17. A review on cholinesterase inhibitors for Alzheimer's disease. Anand P; Singh B Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942 [TBL] [Abstract][Full Text] [Related]
18. Cholinesterase as a Target for Drug Development in Alzheimer's Disease. Sharma P; Tripathi MK; Shrivastava SK Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661 [TBL] [Abstract][Full Text] [Related]
19. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Ismaili L; Refouvelet B; Benchekroun M; Brogi S; Brindisi M; Gemma S; Campiani G; Filipic S; Agbaba D; Esteban G; Unzeta M; Nikolic K; Butini S; Marco-Contelles J Prog Neurobiol; 2017 Apr; 151():4-34. PubMed ID: 26797191 [TBL] [Abstract][Full Text] [Related]
20. New Tacrines as Anti-Alzheimer's Disease Agents. The (Benzo)Chromeno- PyranoTacrines. Oset-Gasque MJ; Marco-Contelles J Curr Top Med Chem; 2017; 17(31):3349-3360. PubMed ID: 29332585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]